Fitbit
The company released three new products today that are available today for preorder on Fitbit’s website and will be sold worldwide in late September.
With the research gathered in its study, Fitbit hopes to create an algorithm that can detect diseases such as COVID-19 before symptoms start using physiological signs.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
The regulator said it was not satisfied with Google's offer to silo Fitbit-collected data so that it could not be used for advertising purposes.
Members in 27 states and Washington D.C. are eligible to receive the Level2 chronic care model at no additional cost.
A new enterprise offering called Ready for Work will use devices, apps and dashboards to conduct daily screening for COVID-19 symptoms.
The in-app study collects wearable data and asks participants about their recent symptom history.
Fitbit's CEO James Park told CNBC that the company will be submitting its technology to the FDA soon.
Also Fitbit struggles as it waits to be acquired by Google, and Livongo sees strong growth.
The Fitbit Heart Study is looking to enroll 200,000 to 250,000 device owners, and will support clinical evaluation and regulatory submissions of the company's PPG atrial fibrillation algorithm.